Jonathan McNeill Biography and Net Worth

President and Chief Operating Officer of Crescent Biopharma

Jonathan McNeill, M.D. joined Crescent as president and chief operating officer in March 2025, bringing extensive experience in corporate strategy, business development and financing in multiple therapeutic areas, including oncology and rare disease. Previously, he was at Dyne Therapeutics for more than five years, most recently as chief business officer, where he led business development, executed multiple financings totaling more than $1 billion and was a key member of the executive team that advanced two neuromuscular disease programs through clinical proof-of-concept trials. Prior to that, Dr. McNeill served on the business development team at Editas Medicine where he played a key role in the execution of the company’s initial public offering and its oncology collaboration with Juno Therapeutics. Dr. McNeill was previously a member of Boston Consulting Group’s healthcare practice. He currently serves as a Venture Partner at Forbion, a leading life sciences investment firm. Dr. McNeill earned his BA in public policy and economics from the University of North Carolina and his M.D. from the University of Pennsylvania.

What is Jonathan McNeill's net worth?: The estimated net worth of Jonathan McNeill is at least $1.99 million as of September 18th, 2026. Dr. McNeill owns 134,588 shares of Crescent Biopharma stock worth more than $1,986,519 as of September 30th. This net worth approximation does not reflect any other assets that Dr. McNeill may own. Learn More about Jonathan McNeill's net worth.
How do I contact Jonathan McNeill?: The corporate mailing address for Dr. McNeill and other Crescent Biopharma executives is 300 Fifth Avenue, Waltham, MA, 02451. Crescent Biopharma can also be reached via phone at (617) 430-5595 and via email at [email protected] . Learn More on Jonathan McNeill's contact information.
Has Jonathan McNeill been buying or selling shares of Crescent Biopharma?: Over the course of the past ninety days, Jonathan McNeill has sold $77,234.59 of Crescent Biopharma stock. Most recently, Jonathan McNeill sold 3,839 shares of the business's stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.71, for a transaction totalling $64,149.69. Following the completion of the sale, the chief operating officer now directly owns 134,588 shares of the company's stock, valued at $2,248,965.48. Learn More on Jonathan McNeill's trading history.
Who are Crescent Biopharma's active insiders?: Crescent Biopharma's insider roster includes Barbara Bispham (Insider), Joshua Brumm (CEO), Ellie Im (Chief Medical Officer), Ryan Lynch (Senior Vice President, Finance and Chief Accounting Officer), Jonathan McNeill (President and Chief Operating Officer), Jan Pinkas (Chief Scientific Officer), and Richard Scalzo (CFO). Learn More on Crescent Biopharma's active insiders.
Are insiders buying or selling shares of Crescent Biopharma?: During the last year, Crescent Biopharma insiders bought shares 1 times. They purchased a total of 1,360,000 shares worth more than $18,237,600.00. During the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 84,882 shares worth more than $1,511,627.40. The most recent insider tranaction occured on September, 18th when CEO Joshua T. Brumm sold 7,837 shares worth more than $130,956.27. Insiders at Crescent Biopharma own 24.8% of the company. Learn More about insider trades at Crescent Biopharma.
Information on this page was last updated on 9/18/2026.

Jonathan McNeill Insider Trading History at Crescent Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/18/2026	Sell	3,839	$16.71	$64,149.69	134,588
9/16/2026	Sell	731	$17.90	$13,084.90	138,427
6/22/2026	Sell	20,549	$17.99	$369,676.51	139,158

Jonathan McNeill Buying and Selling Activity at Crescent Biopharma

Crescent Biopharma Company Overview

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Today's Range

Now: $14.28

$14.24

$14.89

50 Day Range

MA: $17.04

$13.99

$20.88

2 Week Range

Now: $14.28

$8.72

$27.41

Volume

14,103 shs

Average Volume

298,506 shs

Market Capitalization

$530.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24